Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chang Min | - |
dc.contributor.author | Yoo, Moon-Won | - |
dc.contributor.author | Son, Young-Gil | - |
dc.contributor.author | Oh, Sung Jin | - |
dc.contributor.author | Kim, Jong-Han | - |
dc.contributor.author | Kim, Hyoung-Il | - |
dc.contributor.author | Park, Joong-Min | - |
dc.contributor.author | Hur, Hoon | - |
dc.contributor.author | Jee, Ye Seob | - |
dc.contributor.author | Hwang, Sun-Hwi | - |
dc.contributor.author | Jin, Sung-Ho | - |
dc.contributor.author | Lee, Sang Eok | - |
dc.contributor.author | Park, Ji-Ho | - |
dc.contributor.author | Seo, Kyung Won | - |
dc.contributor.author | Park, Sungsoo | - |
dc.contributor.author | Kim, Chang Hyun | - |
dc.contributor.author | Jeong, In Ho | - |
dc.contributor.author | Lee, Han Hong | - |
dc.contributor.author | Choi, Sung Il | - |
dc.contributor.author | Lee, Sang-Il | - |
dc.contributor.author | Kim, Chan Young | - |
dc.contributor.author | Kim, In-Hwan | - |
dc.contributor.author | Son, Myoung-Won | - |
dc.contributor.author | Pak, Kyung Ho | - |
dc.contributor.author | Kim, Sungsoo | - |
dc.contributor.author | Lee, Moon-Soo | - |
dc.contributor.author | Min, Jae-Seok | - |
dc.date.accessioned | 2021-08-30T22:23:00Z | - |
dc.date.available | 2021-08-30T22:23:00Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2093-582X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55526 | - |
dc.description.abstract | Purpose: To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC). Materials and Methods: This retrospective multicenter observational study enrolled 983 patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. We conducted propensity score matching to reduce selection bias. Long-term oncologic outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively. Results: The median and longest follow-up period were 59.0 and 87.6 months, respectively. DFS rate did not differ between patients who received S-i and CAPOX for pathologic stage II (P=0.677) and stage III (P=0.899) GC. Moreover, hazard ratio (HR) for recurrence did not differ significantly between S-1 and CAPOX (reference) in stage II (HR, 1.846; 95% confidence interval [CI], 0.693-4.919; P=0.220) and stage III (HR, 0.942; 95% CI, 0.664-1.337; P=0.738) GC. After adjustment for significance in multivariate analysis, pT (4 vs. 1) (HR, 11.667; 95% CI, 1.595-85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502-5.174; P=0.001), and completion of planned chemotherapy (HR., 2.213; 95% CI, 1.618-3.028; P<0.001) were determined as independent prognostic factors for DFS. Conclusions: S-1 and CAPOX AC regimens did not show significant difference in over-5yr DFS after curative gastrectomy in patients with stage II or III GC. The pT, pN stage, and completion of planned chemotherapy were prognostic factors for GC recurrence. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN GASTRIC CANCER ASSOC | - |
dc.title | Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Chang Min | - |
dc.contributor.affiliatedAuthor | Park, Sungsoo | - |
dc.identifier.doi | 10.5230/jgc.2020.20.e13 | - |
dc.identifier.scopusid | 2-s2.0-85086838656 | - |
dc.identifier.wosid | 000543384600004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTRIC CANCER, v.20, no.2, pp.152 - 164 | - |
dc.relation.isPartOf | JOURNAL OF GASTRIC CANCER | - |
dc.citation.title | JOURNAL OF GASTRIC CANCER | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 152 | - |
dc.citation.endPage | 164 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002595586 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Adjuvant chemotherapy | - |
dc.subject.keywordAuthor | Disease-free survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.